CymaBay Therapeutics, Inc.

NasdaqGS:CBAY Stock Report

Market Cap: US$3.7b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

CymaBay Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

CymaBay Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-9.3%

Buyback Yield

Total Shareholder Yield-9.3%
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Analysis Article • Feb 15

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Today is shaping up negative for CymaBay Therapeutics, Inc. ( NASDAQ:CBAY ) shareholders, with the analysts delivering...
Analysis Article • Dec 22

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Celebrations may be in order for CymaBay Therapeutics, Inc. ( NASDAQ:CBAY ) shareholders, with the analysts delivering...
Analysis Article • Dec 28

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Seeking Alpha • Aug 11

CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01

CymaBay Therapeutics press release (NASDAQ:CBAY): Q2 GAAP EPS of -$0.31 misses by $0.01. Shares +5%. Held $170.8 million in cash, cash equivalents and investments as of June 30, 2022. We believe that cash and investments on hand are sufficient to fund CymaBay’s operating plan through 2023.
Analysis Article • Jul 13

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Jun 27

CymaBay: Long-Term Potential Based On Prior PBC Trial Results

Results from the phase 3 RESPONSE study, which is using Seladelpar for the treatment of patients with primary biliary Cholangitis, are expected in 2023. PBC patients treated with Seladelpar over a 2-year period saw a decrease in GLOBE PBC Score and improved transplant-free survival. The global Primary Biliary Cholangitis treatment market size is estimated to be worth $812.6 million in 2022 and could reach $2.5 billion by 2028. Two other indications in which Seladelpar can be used for are non-alcoholic steatohepatitis and primary sclerosing cholangitis.
Analysis Article • Mar 17

Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Jan 20

Why I've Taken A 'Starter' Position In CymaBay Therapeutics

CymaBay Therapeutics has made continuous progress advancing its lead asset, seladelpar. CymaBay's previous Phase 2 and Phase 3 trials are very promising for the success of its registrational Phase 3 trial now underway. Nonetheless, CBAY stock is beaten down and as such I believe it's a bargain.
Analysis Article • Dec 03

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • May 15

We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jan 29

We're Hopeful That CymaBay Therapeutics (NASDAQ:CBAY) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, CymaBay Therapeutics...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if CBAY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CBAY's dividend payments have been increasing.

Dividend Yield vs Market

CymaBay Therapeutics Dividend Yield vs Market
How does CBAY dividend yield compare to the market?
SegmentDividend Yield
Company (CBAY)n/a
Market Bottom 25% (US)1.3%
Market Top 25% (US)4.0%
Industry Average (Pharmaceuticals)1.9%
Analyst forecast (CBAY) (up to 3 years)0%

Notable Dividend: Unable to evaluate CBAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CBAY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate CBAY's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CBAY has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/03/21 00:47
End of Day Share Price 2024/03/21 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CymaBay Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Julian HarrisonBTIG
John TannerCantor Fitzgerald & Co.